🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

🧪

Trial Match

Clinical trials test new treatments — sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

🎯 Match trials to me

30 recruiting trials

for UTUC

A Phase 3 Single-arm Study of UGN-104 for the Treatment of Low-grade Upper Tract Urothelial Cancer NCT06774131Phase 379 sites📍 Homewood📍 Chandler📍 Queen Creek UroGen Pharma Ltd. · Tests: UGN-104 Cisplatin-Based Chemotherapy Followed by Maintenance Avelumab in UTUC NCT07225374Phase 21 site📍 Seoul Samsung Medical Center · Tests: Avelumab 10 mg/kg, Screening, Best Supportive Care (BSC), Follow-up plan Screening for Urological Malignancies Using a Urine Exfoliated Cell Fluorescence Assay in a Hematuria Population NCT07813260n/a1 site📍 Shanghai Ruijin Hospital Disitamab Vedotin Plus Radiotherapy for Adjuvant Treatment of HER2-Expressing Cisplatin-Ineligible Upper Tract Urothelial Carcinoma NCT07498907Phase 31 site📍 Beijing Peking University First Hospital · Tests: Disitamab Vedotin (RC48), radiotherapy, Gemcitabine (1000 mg/m2), carboplatin Efficacy and Safety of Tislelizumab in Combination With Disitamab-vedotin as Neoadjuvant Therapy for HER2-positive High-risk Upper Tract Urothelial Carcinoma (UTUC) NCT05837806Phase 21 site📍 Tianjin Tianjin Medical University Second Hospital · Tests: tislelizumab+disitamab-vedotin Neoadjuvant Gemcitabine Plus Trastuzumab Rezetecan in HER2-positive UTUC NCT07741448Phase 210 sites📍 Huanggang📍 Jingzhou📍 Shiyan Zhiquan Hu · Tests: Trastuzumab Rezetecan, Gemcitabine, Radical nephroureterectomy A Clinical Study of the Efficacy and Safety of Disitamab Vedotin in Combination With Radiotherapy for the Adjuvant Treatment of HER2 Overexpressing UTUC Patients With High Risk Factors for Recurrence After Radical Surgery NCT06210490Phase 21 site📍 Beijing Peking University First Hospital · Tests: Disitamab Vedotin, Radiotherapy, Standard of Care The Danish Bladder Cancer Group 23 Study - A European Study on Cancer in the Upper Urinary Tract NCT07077447n/a5 sites📍 Aarhus N📍 Herlev📍 København Ø Zealand University Hospital · Tests: Kidney sparing surgery for high-risk upper urinary tract urothelial carcinoma Combination of DV and Tislelizumab for Renal Preservation in High-risk UTUC Patients NCT05912816Phase 21 site📍 Shanghai RenJi Hospital · Tests: RC48 Combined With Tislelizumab POST URS Chemotherapy Instillation NCT06167057NA10 sites📍 Ashdod📍 Beersheba📍 Be’er Ya‘aqov Carmel Medical Center · Tests: Mitomycin/Gemcitabine, Saline Non-invasive Urinary Genomics-Based Risk Assessment for Early Urothelial Carcinoma Diagnosis NCT07614594n/a1 site📍 Zhengzhou Henan Provincial People's Hospital Renal Retention in High Grade Upper Tract Urothelial Cancer NCT05656235Phase 22 sites📍 Washington D.C.📍 Baltimore Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins · Tests: Enfortumab vedotin, Pembrolizumab Low-grade UTUC Treated With Nadofaragene Firadenovec Administered to Renal Pelvis NCT06668493Phase 1, Phase 29 sites📍 Scottsdale📍 Santa Monica📍 Jacksonville Ferring Pharmaceuticals · Tests: Nadofaragene Firadenovec uTRACT Jelmyto Registry: A Registry of Patients With Upper Tract Urothelial Cancer (UTUC) Treated With Jelmyto NCT05874921n/a22 sites📍 Santa Monica📍 Gainesville📍 Miami UroGen Pharma Ltd. · Tests: Jelmyto (mitomycin) for pyelocalyceal solution Radical Radiotherapy Versus Radical Surgery for UTUC NCT06652009n/a2 sites📍 Beijing📍 Beijing Peking University First Hospital · Tests: Radical nephroureterectomy, Radical radiotherapy DV Combined With Toripalimab for Renal Preservation in Solitary Kidney or Renal Insufficiency or Bilateral Multiple UTUC NCT06354231Phase 21 site📍 Shanghai Fudan University · Tests: DV, Toripalimab, Laser surgery Circulating and Urine Tumor DNA Dynamics Predict Minimal Residual Disease and Recurrence Risk in Locally Advanced Upper Tract Urothelial Carcinoma NCT05595408n/a1 site📍 Shanghai RenJi Hospital · Tests: Adjuvant chemotherapy, adjuvant immunotherapy An Open-label Study to Investigate the Efficacy and Safety of Dato-DXd + Rilvegostomig vs SoC in Adult Participants With High-risk MIUC NCT07720284Phase 3160 sites📍 Hot Springs📍 Little Rock📍 Little Rock AstraZeneca · Tests: Dato-DXd, Rilvegostomig, Durvalumab, Nivolumab, Pembrolizumab Liquid Biospy for Urinary Cancers NCT06116396n/a1 site📍 Milan IRCCS San Raffaele · Tests: Genetic analysis on isolated cells Neoadjuvant Tislelizumab in Combination With Nab-Paclitaxel for UTUC NCT07126119Phase 21 site📍 Tianjin Tianjin Medical University Second Hospital · Tests: Nab-Paclitaxel, Tislelizumab, Radical nephroureterectomy (RNU) Radical Nephroureterectomy With vs Without Template Lymph Node Dissection in High-Risk Upper Tract Urothelial Carcinoma (T-LND UTUC) NCT07321210NA1 site📍 Tianjin Tianjin Medical University Second Hospital · Tests: Template Lymph Node Dissection, Selective Lymph Node Resection Neoadjuvant Upper Tract Invasive Cancer Trial (NAUTICAL) NCT04574960Phase 32 sites📍 Ottawa📍 Toronto University Health Network, Toronto · Tests: Gemcitabine, Cisplatin, Carboplatin A Study of RC48-ADC Combined with JS001 for Postoperative Adjuvant Treatment of Upper Tract Urothelial Carcinoma NCT05917158Phase 21 site📍 Nanjing Jinling Hospital, China · Tests: RC48-ADC and JS001 Postoperative Adjuvant Immunotherapy Combined with Radiotherapy Versus Surgery Alone in Locally Advanced UTUC NCT06598761n/a2 sites📍 Beijing📍 Beijing Peking University First Hospital · Tests: Immunotherapy+radiotherapy, surveillance alone A Comprehensive Prospective Assessment of the Physical and Biological Effects of Upper Tract Urothelial Cancer (UTUC) NCT05438537n/a1 site📍 Hong Kong Chinese University of Hong Kong Single-Port RAS Using Da Vinci SP Surgical System for UTUC Patients NCT06987552NA1 site📍 Taipei National Taiwan University Hospital · Tests: Da Vinci SP Surgical System A Multicenter Prospective Cohort Study on Monitoring Recurrence of Urothelial Carcinoma Based on Detection of Urinary Microscopic Residual Disease (MRD) NCT06991868n/a1 site📍 Beijing Peking University First Hospital Ambulatory Flexible URS for UTUC Surveillance NCT06848868Phase 12 sites📍 Hong Kong📍 Hong Kong Chinese University of Hong Kong · Tests: Ambulatory flexible ureterorenoscopy Adjuvant Radioimmunotherapy Compared With Adjuvant Chemotherapy for UTUC NCT06120374n/a3 sites📍 Beijing📍 Beijing📍 Beijing Peking University First Hospital · Tests: Radiotherapy, Chemotherapy, Immunotherapy Phase 2A/B Efficacy and Safety of Dabogratinib in Participants With Low Grade Upper Tract Urothelial Carcinoma NCT07265947Phase 232 sites📍 Loma Linda📍 Los Angeles📍 Tampa Tyra Biosciences, Inc · Tests: Dabogratinib (TYRA-300) 60mg, Dabogratinib (TYRA-300) 80mg
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy